Okomera
Business Services · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
9 b Rue D'alembert, Paris, Ile-de-France...Website
www.okomera.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Okomera
We integrate standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Okomera your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Okomera launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Okomera
Okomera, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Okomera recently announced quarterly report
Check out if Okomera is spiking on competitors!
Funding: Get notified immidiatlly once Okomera has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Okomera has recently received funding, and reach out quickly before it becomes old news!
Click to see if Okomera had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Okomera
Find 2 more new buyers
Company Profile Activity
Activity Insights
Okomera is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Okomera is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Okomera.
Okomera financials insights
Gather financial insights about Okomera, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Grant
$1.6M
Okomera Tech Stack
A closer look at the technologies used by Okomera
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
Funding
Funding
Funding
Okomera News & Media
Okomera Opens Pre-orders for Ocentra, the Central Engine for Automated Organoid Screening
PARIS, June 9, 2025 /PRNewswire/ -- Okomera, a biotech pioneering automated organoid-based drug discovery, today opened pre-orders for its first commercial system, Ocentra, unveiled live at the MPS World Summit in Brussels (10–12 June) and Vivatech Paris (11–14 June). Powered by...Okomera Gets €1.5 Million Grant to Develop Microfluidics & AI Powered CRISPR Editing Platform for Target Validation
PARIS, Oct. 21, 2024 /PRNewswire/ -- Okomera announces Bpifrance funding to develop and standardize novel CRISPR screening assay to accelerate drug discovery in oncology with leading cancer research center of Marseille, CRCM. Okomera is developing desktop platform for automated organoid...Neogap secures Eurostars funding to develop T-cell activity analysis
The Swedish biotech company Neogap Therapeutics has received SEK 5 million from Eurostars in a collaboration project with the French biotech company Okomera. The funding aims to enhance the development of an analysis method for T-cell activity against the patient's tumour. Neogap is developing pTTL, personalised Tumour Trained Lymphocytes, a tailored cell therapy that utilises modified proteins, known as neoantigens, to activate the immune system specifically against cancer cells. The therapy is
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Okomera
Sign Up For FreeTo access detailed company insights
We integrate standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity.... Read More
